Compare LAW & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | BNTC |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 405.7M |
| IPO Year | 2021 | N/A |
| Metric | LAW | BNTC |
|---|---|---|
| Price | $8.36 | $12.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.75 | ★ $28.25 |
| AVG Volume (30 Days) | ★ 351.4K | 235.3K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $152,677,000.00 | N/A |
| Revenue This Year | $8.51 | N/A |
| Revenue Next Year | $7.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.33 | N/A |
| 52 Week Low | $3.31 | $9.70 |
| 52 Week High | $9.11 | $17.15 |
| Indicator | LAW | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 64.42 | 40.35 |
| Support Level | $7.28 | $12.78 |
| Resistance Level | $8.97 | $13.68 |
| Average True Range (ATR) | 0.38 | 0.75 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 66.88 | 28.74 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.